Zimmer Biomet Holdings Inc. Stock Advances 3.7%, Outperforms Peers
Dow Jones2026/10/05 20:35This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Zimmer Biomet Holdings Inc. rallied 3.7% to $91.57 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.7% to 7,773.95 and the Dow Jones Industrial Average rising 0.2% to 51,267.90. This was the stock's second consecutive day of gains. Zimmer Biomet Holdings Inc. closed 14.3% below its 52-week high of $106.88, which the company reached on October 22nd. The stock outperformed some of its peers, as Johnson & Johnson fell 1.2% to $252.93, Medtronic PLC rose 1.8% to $87.97, and Stryker Corp. rose 3.55% to $285.22. Trading volume totaled 2.3 million, compared to the 50-day average of 2.2 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 05, 2026 16:35 ET (20:35 GMT)
This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Zimmer Biomet Holdings Inc. rallied 3.7% to $91.57 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.7% to 7,773.95 and the Dow Jones Industrial Average rising 0.2% to 51,267.90.
This was the stock's second consecutive day of gains.
Zimmer Biomet Holdings Inc. closed 14.3% below its 52-week high of $106.88, which the company reached on October 22nd.
The stock outperformed some of its peers, as Johnson & Johnson fell 1.2% to $252.93, Medtronic PLC rose 1.8% to $87.97, and Stryker Corp. rose 3.55% to $285.22.
Trading volume totaled 2.3 million, compared to the 50-day average of 2.2 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 05, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
